Key Points
- CEO Richard Nolan Townsend sold 3,345 Lexeo Therapeutics shares at an average price of $4.95, receiving $16,557.75. The sale covered tax withholding obligations tied to vested equity awards and reduced his direct holdings by 0.89% to 374,472 shares.
- Lexeo shares opened at $5.37 after an 8.9% rise, but the company recently reported a quarterly loss of $0.30 per share, slightly worse than analysts’ $0.29 estimate. The stock has traded between $3.99 and $10.99 over the past year.
- Analyst sentiment remains broadly positive, with an average “Buy” rating and a consensus price target of $18.75, despite mixed individual revisions. Institutional investors own approximately 60.67% of the company.
Lexeo Therapeutics, Inc. (NASDAQ:LXEO - Get Free Report) CEO Richard Nolan Townsend sold 3,345 shares of Lexeo Therapeutics stock in a transaction that occurred on Tuesday, August 18th. The shares were sold at an average price of $4.95, for a total value of $16,557.75. Following the sale, the chief executive officer directly owned 374,472 shares in the company, valued at approximately $1,853,636.40. This trade represents a 0.89% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards.
Richard Nolan Townsend also recently made the following trade(s):
- On Wednesday, July 1st, Richard Nolan Townsend sold 25,947 shares of Lexeo Therapeutics stock. The shares were sold at an average price of $4.48, for a total transaction of $116,242.56.
Lexeo Therapeutics Trading Up 8.9%
Shares of NASDAQ:LXEO opened at $5.37 on Thursday. Lexeo Therapeutics, Inc. has a twelve month low of $3.99 and a twelve month high of $10.99. The firm has a market cap of $440.61 million, a P/E ratio of -4.67 and a beta of 1.46. The company has a 50 day moving average of $4.70 and a 200-day moving average of $5.56.
Lexeo Therapeutics (NASDAQ:LXEO - Get Free Report) last issued its quarterly earnings results on Wednesday, August 12th. The company reported ($0.30) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.29) by ($0.01). Equities research analysts forecast that Lexeo Therapeutics, Inc. will post -1.18 EPS for the current year.
Analysts Set New Price Targets
A number of analysts have commented on LXEO shares. JPMorgan Chase & Co. reduced their price objective on shares of Lexeo Therapeutics from $12.00 to $9.00 and set an "overweight" rating for the company in a research note on Thursday, June 25th. Weiss Ratings raised Lexeo Therapeutics from a "sell (e+)" rating to a "sell (d-)" rating in a research note on Thursday, August 13th. Wall Street Zen downgraded Lexeo Therapeutics from a "hold" rating to a "strong sell" rating in a report on Saturday, August 15th. Finally, Chardan Capital raised shares of Lexeo Therapeutics to a "strong-buy" rating in a research report on Tuesday, July 28th. Two investment analysts have rated the stock with a Strong Buy rating, six have given a Buy rating and one has given a Sell rating to the stock. According to data from MarketBeat, the stock presently has an average rating of "Buy" and a consensus price target of $18.75.
Check Out Our Latest Stock Report on Lexeo Therapeutics
Institutional Trading of Lexeo Therapeutics
A number of institutional investors and hedge funds have recently made changes to their positions in LXEO. Hennion & Walsh Asset Management Inc. acquired a new stake in Lexeo Therapeutics in the 2nd quarter worth approximately $1,237,000. Dimensional Fund Advisors LP raised its position in shares of Lexeo Therapeutics by 27.9% in the first quarter. Dimensional Fund Advisors LP now owns 1,103,584 shares of the company's stock valued at $6,332,000 after purchasing an additional 240,692 shares during the period. Spruce Street Capital LP raised its position in shares of Lexeo Therapeutics by 430.6% in the first quarter. Spruce Street Capital LP now owns 928,593 shares of the company's stock valued at $5,330,000 after purchasing an additional 753,593 shares during the period. Affinity Asset Advisors LLC boosted its holdings in shares of Lexeo Therapeutics by 57.8% during the 1st quarter. Affinity Asset Advisors LLC now owns 5,050,211 shares of the company's stock worth $28,988,000 after buying an additional 1,850,211 shares during the period. Finally, Orbimed Advisors LLC raised its holdings in Lexeo Therapeutics by 69.5% in the 1st quarter. Orbimed Advisors LLC now owns 3,602,450 shares of the company's stock worth $20,678,000 after acquiring an additional 1,477,450 shares during the period. Institutional investors and hedge funds own 60.67% of the company's stock.
About Lexeo Therapeutics
(
Get Free Report)
Lexeo Therapeutics, Inc is a clinical‐stage biotechnology company dedicated to developing novel, precision‐designed therapies for central nervous system disorders. The company’s research platform leverages advanced medicinal chemistry to create next‐generation psychedelic-inspired compounds aimed at treating a range of mental health conditions, including anxiety, depression and substance use disorders.
The company’s pipeline features proprietary synthetic molecules engineered to target specific neural pathways while improving safety and tolerability profiles over traditional treatments.
Read More
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
